How to Leverage Tumor Models for Pancreatic Cancer Research
Pancreatic cancer is a challenging disease due to resistance to a range of anticancer agents and immunotherapies. To uncover new treatment options, preclinical models need to better recapitulate human disease, including the tumor microenvironment (TME) which contributes to drug resistance. Cutting-edge immuno-oncology technologies also need to be explored.
This White Paper presents orthotopic tumor homografts as a clinically-relevant pancreatic cancer preclinical model, which more accurately replicates the TME in vivo. These immunocompetent models allow advanced assessment of novel agents targeting the disease, including immunotherapies.
CAR-T cell therapy for pancreatic cancer is also discussed as a novel treatment modality. Discover how patient-derived xenografts (PDX) recapitulating human mesothelin expression levels are used to assess anti-MSLN CAR-T cell therapy efficacy.
Download This White Paper to Understand:
- How orthotopic tumor homograft models maintain relevant tumor stroma with a rich TME to mimic human pancreatic cancer
- The immune profile of orthotopic pancreatic cancer tumor homograft models, and how this may affect treatment response
- How anti-MSLN CAR-T cells efficiently inhibit the growth of pancreatic cancer in a clinically relevant PDX model